ReviewCureus2026
Elevated Lipoprotein(a) and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipoprotein(a) (Lp(a)) is a genetically determined lipoprotein with proatherogenic and prothrombotic properties. Its prognostic role in patients undergoing percutaneous coronary intervention (PCI) remains incompletely defined. This systematic review evaluates the association between elevated Lp(a) and cardiovascular outcomes after PCI. A comprehensive search of PubMed, Embase, Scopus, IEEE Xplore, and Web of Science was conducted for studies published between 2021 and 2025. Observational studies evaluating elevated Lp(a) and cardiovascular outcomes in PCI patients were included. Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS). Eight studies comprising 23,421 patients were included. Elevated Lp(a) thresholds ranged from ≥30 mg/dL to ≥50 mg/dL. Seven studies demonstrated a significant positive association between elevated Lp(a) and adverse outcomes, with hazard ratios for major adverse cardiovascular events (MACEs) ranging from 1.14 to 4.29. Elevated Lp(a) was consistently associated with increased risks of myocardial infarction (HR 1.79), stent thrombosis (HR 1.83), and repeat revascularisation. One study in patients with well-controlled low-density lipoprotein cholesterol (LDL-C; <70 mg/dL) found no significant association. Subgroup analyses revealed that the prognostic value of Lp(a) was most pronounced in high-risk patients and those with diabetes. One study demonstrated that a greater decrease in Lp(a) over 12 months was associated with lower MACE risk. NOS assessment rated seven studies as high quality and one as moderate quality. Elevated Lp(a) is independently associated with increased risk of adverse cardiovascular outcomes after PCI, although this risk may be attenuated by aggressive LDL-C lowering. These findings may support the consideration of routine Lp(a) measurement in PCI patients for risk stratification and to help inform secondary prevention strategies, although confirmation from prospective and interventional studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.